Acusphere, Inc. (ACUSD.PK) today announced that it has submitted the Marketing Authorisation Application (MAA) for its lead product candidate, Imagify™ (Perflubutane Polymer Microspheres) lyophilisate ...
Acusphere Inc. announced the submission of a New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for approval to market its lead product candidate, Imagify™ (Perflubutane Polymer ...
SAN FRANCISCO (MarketWatch) -- Acusphere Inc. ACUS, shares tumbled 27% to $3.02 in Tuesday morning trade. The Watertown, Mass.-based pharmaceutical company said Imagify met the primary endpoints for ...
LEXINGTON, Mass.--(BUSINESS WIRE)--Acusphere, Inc. (ACUS.PK), a specialty pharmaceutical company, today announced that it had reached an agreement with the U.S. Food & Drug Administration (FDA) ...
NEW YORK, May 1 (Reuters) - Acusphere Inc.'s experimental imaging agent for measuring blood flow in the heart met or exceeded two of its three main goals in a clinical trial that will be used to seek ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results